We've updated our Privacy Policy to make it clearer how we use your personal data. We use cookies to provide you with a better experience. You can read our Cookie Policy here.


InfineQ: Cloud-Based MS-DIA Data Processing Software With Near Real-Time Results

InfineQ: Cloud-Based MS-DIA Data Processing Software With Near Real-Time Results content piece image
Listen with
Register for free to listen to this article
Thank you. Listen to this article using the player above.

Want to listen to this article for FREE?

Complete the form below to unlock access to ALL audio articles.

Read time: Less than a minute

Targeted proteomics start-up ProteiQ Biosciences has announced the launch of InfineQ, its cloud-based solution software for near real-time processing of proteomics data. Proteomics allows quantitative multiplexed analysis of thousands of proteins in biological samples. The new solution provides the scale and speed needed for biomarker discovery, potentially reducing the costs of breakthrough treatments.

InfineQ is built on top of DIA-NN—an algorithm for analysis of MS-DIA proteomics data. Developed by the Cambridge Centre for Proteomics (CCP) and The Francis Crick Institute, the new machine-learning based algorithm allows efficient processing of the MS-DIA (data-independent acquisition) proteomics signal, known for its complexity.

“The new advancement holds large promise since proteomics data can be analyzed faster and with more precision. In combination with genomics, a deeper understanding of organisms and their dynamics can be obtained, leading to finding the cure for the most challenging diseases faster,” said Arnoud Groen, Co-founder and CSO of ProteiQ Biosciences.

One of the first applications of the technology is addressing the health complications related to silicone breast implants in women with breast augmentation. Start-up company Bioflagz is developing a direct-to-consumer protein biomarker test to better predict these health complications. “Periodic testing costs time and money and 57% of women develop late-stage complications that could have been detected much earlier. An at-home proteomics test will allow women to monitor this themselves and ask for medical assistance when needed,” said Dimitar Tasev, CEO of Bioflagz.